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ABSTRACT
In chronic lymphocytic leukemia (CLL), Notch1 and Notch2 signaling is 
constitutively activated and contributes to apoptosis resistance. We show that 
genetic inhibition of either Notch1 or Notch2, through small-interfering RNA, 
increases apoptosis of CLL cells and is associated with decreased levels of the anti-
apoptotic protein Mcl-1. Thus, Notch signaling promotes CLL cell survival at least in 
part by sustaining Mcl-1 expression. In CLL cells, an enhanced Notch activation also 
contributes to the increase in Mcl-1 expression and cell survival induced by IL-4. 
 Mcl-1 downregulation by Notch targeting is not due to reduced transcription or 
degradation by caspases, but in part, to increased degradation by the proteasome. Mcl-
1 downregulation by Notch targeting is also accompanied by reduced phosphorylation 
of eukaryotic translation initiation factor 4E (eIF4E), suggesting that this protein is 
another target of Notch signaling in CLL cells. 
Overall, we show that Notch signaling sustains CLL cell survival by promoting 
Mcl-1 expression and eIF4E activity, and given the oncogenic role of these factors, 
we underscore the therapeutic potential of Notch inhibition in CLL.
INTRODUCTION
Notch signaling is involved in various cellular 
processes, including cell fate specification, differentiation, 
proliferation, and apoptosis. Abnormal Notch signaling 
is oncogenic in several cancers, including hematologic 
malignancies [1]. Disregulated Notch signaling has also 
been associated with chronic lymphocytic leukemia 
(CLL), a frequent adult leukemia characterized by the 
accumulation of CD19+/CD5+ B lymphocytes resistant 
to apoptosis [2]. The involvement of Notch in CLL has 
been recently demonstrated by findings that a NOTCH1 
PEST domain mutation, generating a highly active 
truncated protein, and affecting up to 10-15% of patients, 
is associated with poor prognosis, disease progression 
and refractoriness to chemotherapy [3-7]. Previous 
evidence that constitutive activation of Notch1 and 
Notch2 signaling contributes to apoptosis resistance in 
CLL also underscores the importance of Notch in this 
leukemia [8, 9], encouraging further investigation of its 
therapeutic potential. Indeed, a better understanding of 
the mechanisms involved in the anti-apoptotic signaling 
of Notch in CLL cells may provide insight for designing 
future Notch-targeted therapies. 
In cancer, Notch signaling prevents apoptosis 
through different networks, involving cell cycle and 
survival pathways, and interactions with mitochondria. 
Notch suppresses p53 [10] or JNK function [11] as well 
as the expression of the pro-apoptotic proteins Bax, Bim 
and Noxa [12, 13]. Notch increases the activation of the 
pro-survival PI3K/AKT [14] and NF-kB pathways [15] 
and the expression of the anti-apoptotic proteins Bcl-2 
and Bcl-xL [12], stabilizes the apoptosis inhibitor protein 
XIAP [16] and induces mitochondrial integrity and 
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functions [17]. Some of these functions are mediated by 
the transcriptional activity of Notch-intracellular domain 
(ICD) [10, 14, 15], which, after Notch-ligand interactions, 
is released from the membrane to the nucleus. Other 
functions involve a non-canonical Notch-ICD-activated 
signaling which operates in the cytoplasm [11, 16] and 
can also converge on the mitochondria by promoting cell 
survival [17]. 
A crucial role in controlling mitochondrial integrity 
and apoptosis is played by the balance between pro-
apoptotic and anti-apoptotic Bcl-2 family members [18]. 
In CLL as well as in other hematologic malignancies, the 
over-expression of the anti-apoptotic Mcl-1 and Bcl-2 
proteins is one of the major causes of apoptosis resistance 
[19, 20], poor prognosis [21, 22] and chemoresistance 
[23-25]. Mcl-1 and Bcl-2 bind and sequester the pro-
apoptotic proteins Bax and Bak blocking their ability 
to form pores in the mitochondrial membrane with the 
consequent release of cytochrome c into the cytoplasm. 
Degradation of Mcl-1 frees Bax and Bak allowing their 
polymerization and activating apoptosis [18]. Mcl-1 is a 
short-lived protein tightly regulated by transcriptional [26, 
27], translational [28, 29], and degradation mechanisms 
[30, 31]. Interestingly, Mcl-1 mRNA translation is highly 
dependent on the eukaryotic initiation factor 4E (eIF4E), 
a key component of the mRNA cap-binding complex, 
which preferentially enhances translation of a subset of 
mRNAs with complex 5’ untranslated regions, such as 
those of Mcl-1 and several other transformation-related 
and survival proteins [32-34]. eIF4E has been associated 
with cancer development and progression, and proposed 
as an important therapeutic target [35, 36]. Recently, it 
has been demonstrated that CLL cells also express high 
levels of eIF4E, and that its pharmacologic targeting 
increases in vitro fludarabine cytotoxicity, suggesting an 
involvement of eIF4E in chemoresistance of these cells 
[37]. Considering the critical role of Mcl-1 and eIF4E 
in CLL and in other malignancies, in this study, we 
investigated whether Mcl-1 and eIF4E are targets of the 
anti-apoptotic Notch signaling in CLL.
RESULTS
Notch1 and Notch2 downregulation decreases 
viability of CLL cells from different patient 
subgroups
We used small-interfering RNA (siRNA) and 
nucleofection to silence expression of Notch1 and Notch2 
in all 22 patients included in the study. Table 1 gives 
clinical and biological characteristics of CLL patients. 
Downregulation of the expression of each Notch receptor, 
achieved at different levels in all samples examined (Table 
2), did not affect the levels of the other receptor (Figure 
1A), suggesting that the expression of each of them is 
independent of the other. As previously reported [8, 9] 
and shown in Table 2 and Figure 1B, silencing of either 
Notch1 (siNotch1) or Notch2 (siNotch2) decreased, to 
a similar extent, CLL cell viability compared with cells 
transfected with control siRNA (siCtrl). This effect was 
observed in 18 of 22 samples (Table 2), suggesting that 
both receptors contribute to CLL cell survival in the vast 
majority of patients (81.8%). The four patients with Notch-
independent viability (CLL4, 17, 20, 22) did not belong 
to any specific subgroup regarding clinical and biological 
characteristics (Table 1). Decrease in cell viability induced 
by silencing of each receptor varied among the different 
CLL samples, ranging from 17.7 to 65.2% for Notch1 and 
from 16.1 to 51.4% for Notch2 (Table 2). However, similar 
responses were observed irrespective of Binet stage, 
previous therapy, IgVH mutational status and ZAP70 
and CD38 expression (Table 3), suggesting that Notch 
targeting is effective in CLL cells despite the presence of 
adverse prognostic factors. Even in the three samples with 
NOTCH1 PEST domain mutation (CLL1, 7, 11; Table 1), 
either Notch1 or Notch2 downregulation reduced CLL cell 
viability at levels similar to those observed in NOTCH1-
unmutated samples (Table 3). These results suggest that 
NOTCH1 mutation does not influence the sensitivity of 
CLL cells to Notch targeting, at least when it is harboured 
by a small fraction of leukemic cells, as indicated by the 
low NOTCH1 mutant allele burden detected in all three 
mutated samples examined (Table 1). 
The evidence that Notch1 and Notch2 exert 
redundant effects in promoting CLL cell survival prompted 
us to examine the effect of combined Notch1 and Notch2 
silencing. We simultaneously transfected CLL cells with 
Notch1 and Notch2 siRNA (siNotch1/2), and performed 
these experiments in six CLL samples (patients 6, 7, 9, 
11, 16, 18), selected to include patients with different 
clinical and biological characteristics. Results showed that 
although the combined siNotch1/2 transfection efficiently 
downregulated the expression of both receptors (Figure 
1A), it did not further decrease CLL cell viability with 
respect to transfection of each single receptor (Figure 1B).
Notch1 and Notch2 silencing decreases Mcl-1 but 
not Bcl-2 protein expression in CLL cells
Based on the evidence that Mcl-1 and Bcl-2 proteins 
are highly expressed in CLL cells and play a crucial 
role in apoptosis resistance and CLL pathogenesis [19, 
23], we analyzed the effect of Notch downregulation 
on the expression of these proteins (n = 22). We found 
that in 15 of the 18 samples where Notch1 and Notch2 
downregulation reduced CLL cell viability, there was 
a decrease in Mcl-1 levels compared with siCtrl cells, 
whereas in the four samples with Notch-independent 
viability, Mcl-1 levels remained unchanged (Table 2, 
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Table 1: Characteristics of CLL patients
Patients Binet stage
Previous 
treatmenta
IgVH 
statusb
ZAP70 
expressionc
CD38 
expressiond
NOTCH1 status
(% mutant allele burden)e
Cytogenetic 
alterationsf
CLL1 B no Unm + - Mut (1.9) Normal
CLL2 C yes Unm + - Unm del 11q22-23del 13q14
CLL3 A no Unm + ND Unm ND
CLL4 C yes Unm + + Unm del 11q22-23del 13q14
CLL5 C yes Unm + + Unm del 13q14del 14q32
CLL6 A no Mut + - Unm Normal
CLL7 B yes Unm + + Mut (2.4) del 11q22-23
CLL8 B yes Unm + + Unm ND
CLL9 C yes Unm - - Unm ND
CLL10 C yes Mut - - Unm del 13q14del 17p13
CLL11 B yes Unm - - Mut (1.3)
del 11q22-23
del 13q14
del 14q32
CLL12 C yes Unm + - Unm del 11q22-23del 13q14
CLL13 A yes Unm + + Unm Normal
CLL14 C yes Unm + - Unm del 14q32
CLL15 B no Mut - - Unm Normal
CLL16 C yes Mut + + Unm ND
CLL17 A no Mut - - Unm del 13q14
CLL18 A no Mut - - Unm del 13q14
CLL19 C yes Mut + - Unm ND
CLL20 B yes Mut - + Unm Normal
CLL21 B yes Unm + - Unm del 13q14del 14q32
CLL22 B no Mut + - Unm Normal
Mut, mutated; Unm, unmutated; ND, not determined.
aTreated patients had not received treatment for at least 3 months before the study.
bMutated was defined as having a frequency of mutations >2% from germline VH.
cPositivity refers to detection of >20% ZAP70+/CD19+.
dPositivity refers to detection of >20% CD38+/CD19+.
ec.7544_7545delCT in NOTCH1 exon 34.
fAssessed by FISH.
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Table 2: Effect of Notch1 and Notch2 silencing on CLL cell viability and Mcl-1 protein expression
Patients siRNA Receptor
% reduction in Notch 
expression
% reduction 
in CLL cell 
viability
% reduction in 
Mcl-1 protein 
expressionTM IC
CLL 1
siNotch1 Notch1 55.0 67.0 32.6 39.0
siNotch2 Notch2 51.2 61.1 17.9 38.0
CLL 2
siNotch1 Notch1 76.0 53.8 19.8 none
siNotch2 Notch2 30.2 38.1 16.2 none
CLL 3
siNotch1 Notch1 98.0 99.3 65.2 70.0
siNotch2 Notch2 71.0 64.0 51.4 29.8
CLL 4
siNotch1 Notch1 87.0 69.5 none none
siNotch2 Notch2 84.0 64.4 none none
CLL 5
siNotch1 Notch1 57.0 80.1 32.7 36.9
siNotch2 Notch2 43.7 65.3 35.1 51.0
CLL 6
siNotch1 Notch1 61.5 52.8 38.1 44.4
siNotch2 Notch2 84 78 43.7 50.9
CLL 7
siNotch1 Notch1 73.2 89.1 29.7 44.2
siNotch2 Notch2 69.0 56.7 23.1 32.6
CLL 8
siNotch1 Notch1 78.2 72.1 29.3 36.0
siNotch2 Notch2 52.0 47.3 24.8 23.2
CLL 9
siNotch1 Notch1 67.0 73.0 33.8 27.7
siNotch2 Notch2 81.0 72.5 39.5 34.0
CLL 10
siNotch1 Notch1 78.0 58.0 25.0 none
siNotch2 Notch2 75.0 51.0 28.4 none
CLL 11
siNotch1 Notch1 48.0 59.0 20.8 22.9
siNotch2 Notch2 41.0 54.0 38.2 41.7
CLL 12
siNotch1 Notch1 51.0 65.0 31.5 none
siNotch2 Notch2 35.3 40.1 17.1 none
CLL 13
siNotch1 Notch1 31.0 35.2 17.7 23.0
siNotch2 Notch2 75.7 61.2 16.1 48.0
CLL 14
siNotch1 Notch1 79.0 72.0 26.1 92.0
siNotch2 Notch2 88.0 98.3 20.7 80.0
CLL 15
siNotch1 Notch1 44.4 52.0 58.4 41.9
siNotch2 Notch2 72.7 59.8 34.9 26.0
CLL 16
siNotch1 Notch1 58.0 69.0 43.9 59.4
siNotch2 Notch2 65.0 71.0 36.1 50.0
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CLL 17
siNotch1 Notch1 47.1 53.0 none none
siNotch2 Notch2 69.0 71.0 none none
CLL 18
siNotch1 Notch1 89.0 74.5 23.9 52.9
siNotch2 Notch2 73.9 52.8 31.3 71.6
CLL 19
siNotch1 Notch1 36.0 31.3 18.4 32.0
siNotch2 Notch2 56.4 45.1 20.5 35.4
CLL 20
siNotch1 Notch1 95.3 71.0 none none
siNotch2 Notch2 50.7 45.4 none none
CLL 21
siNotch1 Notch1 68.3 75.3 33.6 21.0
siNotch2 Notch2 57.3 61.3 44.3 44.0
CLL 22
siNotch1 Notch1 45.6 61.0 none none
siNotch2 Notch2 81.9 82.3 none none
Expression of Notch1 and Notch2 and Mcl-1 was analyzed by western blot in CLL cells transfected with Notch1 (siNotch1), 
Notch2 (siNotch2) or control siRNA (siCtrl). The band intensities of Notch1 and Notch2 (TM and IC) and Mcl-1 were 
quantified by densitometric analysis and normalized to GAPDH. Values represent the percentage reduction of Notch1 and Mcl-
1 expression in siNotch1 cells, and of Notch2 and Mcl-1 expression in siNotch2 cells, compared with siCtrl cells. Viable CLL 
cells were quantified by flow cytometry using Annexin V/PI staining, and the percentage reduction in viability of siNotch1 and 
siNotch2 cells was calculated relative to siCtrl. None indicates reductions in cell viability or Mcl-1 expression lower than 5%.
Figure 1: Notch1 and Notch2 silencing decreases cell viability and expression of Mcl-1 protein in CLL cells. CLL cells 
were transfected with control siRNA (siCtrl), Notch1 siRNA (siNotch1), Notch2 siRNA (siNotch2) or combined siNotch1 and siNotch2 
(siNotch1/2) as described in “siRNA transfection” and then cultured in complete medium for 72 hours. A., C. Western blot analysis of 
Notch1, Notch2, Mcl-1 and Bcl-2 expression was performed on 15 µg whole-cell lysates separated on a 7.5% SDS-PAGE. The antibodies 
used for Notch1 and Notch2 recognized the 120-kDa transmembrane/cytoplasmic subunit (TM) and the 100-kDa active intracellular 
domain (IC). Protein loading was assessed by reprobing the blots with an anti-GAPDH antibody. Vertical line inserted in Notch2 blot of 
CLL7 indicates a repositioned gel lane. Data of CLL7 and 18 are representative of six samples. D. The blots of Mcl-1 were subjected to 
densitometric analysis and densitometry units (U) were calculated relative to GAPDH. Data are the mean ± SD of six samples. *P < 0.05, 
**P < 0.01 (each siNotch transfection condition versus siCtrl) according to Student t test. B. Cell viability was evaluated by flow cytometric 
analysis of Annexin V/PI (An V/PI) staining. Viability (An V-/PI-) of siCtrl cells was set to 100%. Data are the mean ± SD of six samples. 
**P < 0.01 (each siNotch transfection condition versus siCtrl) according to Student t test. 
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Figures 1C and 1D). When we transfected CLL cells with 
combined siNotch1/2 (n = 6), we observed that reduction 
of Mcl-1 levels was more pronounced (Figures 1C and 
1D). In contrast, in all 22 patients, Bcl-2 levels were 
not affected by either each single or combined Notch 
receptor downregulation (Figure 1C and data not shown). 
Altogether, these data indicate that apoptosis of CLL cells 
induced by Notch silencing involves downregulation of 
Mcl-1 but not Bcl-2 expression. 
Combined Notch1 and Notch2 silencing prevents 
the increase in Mcl-1 levels and cell viability 
induced in CLL cells by IL-4
Several micro-environmental stimuli have been 
shown to promote ex vivo CLL cell survival by increasing 
Mcl-1 expression [38, 39]. The involvement of Notch 
signaling in Mcl-1-mediated CLL cell survival induced 
by the microenvironment has never been explored. We 
examined whether the T-cell derived cytokine IL-4, 
known inducer of cell survival and Mcl-1 expression in 
CLL [39], enhanced Notch expression in promoting these 
effects, and if so, whether this increase was required for 
Mcl-1-mediated CLL cell survival induced by IL-4. CLL 
cells, transfected with siCtrl or combined siNotch1/2, 
were cultured for 72 hours with or without IL-4, and then 
examined for Notch1, Notch2 and Mcl-1 expression, and 
cell viability/apoptosis (n = 6). In agreement with previous 
studies [39], we found that in siCtrl cells, IL-4 increased 
both Mcl-1 levels (Figures 2A and 2B) and cell viability 
(Figure 2D). In siCtrl cells, IL-4 significantly upregulated 
also Notch1 and Notch2 expression (Figures 2A and 2C), 
and interestingly, combined Notch1/2 silencing partially 
abrogated the increase in both Mcl-1 expression and cell 
viability induced by the cytokine (Figures 2A-2D). These 
Table 3: Notch1 and Notch2 silencing decreases CLL cell viability independently of clinical characteristics and 
prognostic factors
Binet stages 
and prognostic 
factors
Number of 
patients
% Viability related to siCtrl
(mean ± SD)a
siNotch1 P siNotch2 P
Binet stage
A 5 70.5 ± 23.7 0.778 (A vs B) 71.3 ± 20.4 0.594 (A vs B)
B 8 73.8 ± 18.2 0.974 (B vs C) 76.9 ± 16.1 0.924 (B vs C)
C 9 74.1 ± 11.8 0.707 (C vs A) 76.2 ± 12.2 0.580 (C vs A)
Previous 
treatmentb
No 7 68.1 ± 24.6 74.2 ± 20.0
Yes 15 75.5 ± 11.4 0.337 75.9 ± 13.1 0.814
IgVH statusc
Unm 13 71.2 ± 14.1 73.5 ± 14.2
Mut 9 76.1 ± 20.0 0.505 78.0 ± 16.9 0.501
ZAP70 expressiond
Negative 7 76.1 ± 19.2 75.0 ± 16.6
Positive 15 71.8 ± 15.6 0.579 75.4 ± 15.0 0.954
CD38 expressione
Negative 14 73.8 ± 14.2 74.7 ± 14.3
Positive 7 77.4 ± 15.8 0.599 80.4 ± 14.4 0.402
NOTCH1 statusf
Unm 19 73.3 ± 17.7 75.6 ± 15.9
Mut 3 72.3 ± 6.2 0.925 73.6 ± 10.5 0.839
Mut, mutated; Unm, unmutated.
aPercentage of viable cells determined by Annexin V/PI staining in siNotch1 or siNotch2 transfected CLL cells related to 
siCtrl cells as 100% viability.
bTreated patients had not received treatment for at least 3 months before the study.
cMutated was defined as having a frequency of mutations >2% from germline VH.
dPositivity refers to detection of >20% ZAP70+/CD19+.
ePositivity refers to detection of >20% CD38+/CD19+.
fc.7544_7545delCT in NOTCH1 exon 34.
Oncotarget16565www.impactjournals.com/oncotarget
results indicate that in CLL cells, IL-4 enhances Notch 
expression and that this event is required to induce the 
increase in Mcl-1-mediated cell survival. 
Mcl-1 downregulation by Notch silencing is not 
due to transcriptional control or degradation by 
caspases but in part to degradation by proteasome
Mcl-1 protein expression is regulated at multiple 
levels, including transcription, translation and degradation 
[26-31]. To define whether the reduced Mcl-1 expression 
induced by Notch targeting was due to transcriptional 
inhibition, we analyzed Mcl-1 mRNA expression by real-
time PCR (n = 6). In siNotch1 as well as in siNotch2 cells, 
Mcl-1 mRNA levels were similar to those observed in 
siCtrl cells (Figure 3A), suggesting that Notch silencing 
reduces Mcl-1 expression at posttranscriptional level. 
It has been shown that Mcl-1 can be degraded by 
caspases during apoptosis [40]. To test whether Notch 
silencing decreased Mcl-1 levels through degradation 
Figure 2: Combined Notch1/2 silencing prevents the increase in Mcl-1 levels and cell viability induced by IL-4 in CLL 
cells. CLL cells, transfected with control siRNA (siCtrl) or combined Notch1 and Notch2 siRNA (siNotch1/2) as described in “siRNA 
transfection” , were cultured for 72 hours in complete medium with or without 25 ng/ml IL-4 (n = 6). A. Expression of Notch1, Notch2 
and Mcl-1 was analyzed as described in Figure 1A,C. Vertical line inserted in Notch1 blot of CLL18 indicates a repositioned gel lane. The 
blots of Mcl-1 B. and those of Notch1 and Notch2 C. were subjected to densitometric analysis, and densitometry units (U) were calculated 
relative to GAPDH. A. Data of CLL7 and 18 are representative of six samples. B., C. Data are the mean ± SD of six samples. *P <0.05, **P 
< 0.01 calculated by Student t test. D. Cell viability was evaluated by flow cytometric analysis of Annexin V/PI (An V/PI) staining. Viability 
(An V-/PI-) of IL-4-untreated siCtrl cells was set to 100%. Data are the mean ± SD of six samples. **P < 0.01 calculated by Student t test. 
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by caspases, we cultured siNotch1, siNotch2 and siCtrl 
cells with or without the pan-caspase inhibitor z-VAD-
fmk (n = 6). Results showed that whereas in siCtrl cells, 
z-VAD-fmk increased Mcl-1 levels, in siNotch1 as well 
as in siNotch2 cells treated with z-VAD-fmk, Mcl-1 
levels continued to be downregulated, although PARP 
cleavage, an indicator of caspase activation, continued to 
be inhibited as in siCtrl cells (Figures 3B and 3C). These 
results suggest that reduction in Mcl-1 expression induced 
by Notch targeting was independent of caspase activation. 
Figure 3: Mcl-1 downregulation by Notch silencing partially depends on proteasome degradation. A. Mcl-1 downregulation 
by Notch silencing is independent of reduced transcription. CLL cells were transfected with control siRNA (siCtrl), Notch1 siRNA 
(siNotch1) or Notch2 siRNA (siNotch2) as described in “siRNA transfection” and then cultured in complete medium for 72 hours (n = 
6). Mcl-1 mRNA levels were evaluated by real-time PCR, normalized to GAPDH and represented as fold change with respect to siCtrl 
cells. Data are the mean ± SD of six samples. Differences between each siNotch transfection and siCtrl were not significant. B., C. Mcl-1 
downregulation by Notch silencing is independent of degradation by caspases. siCtrl, siNotch1 or siNotch2 transfected cells were cultured 
for 72 hours in complete medium with 50 µM pan-caspase inhibitor z-VAD-fmk or 0.005% DMSO as control (n = 6). B. PARP cleavage, 
indicator of caspase activity, and Mcl-1 expression were analyzed by western blot on 15 µg whole-cell lysates. Protein loading was assessed 
by reprobing the blots with an anti-GAPDH antibody. Data of CLL18 are representative of six samples. C. The blots of Mcl-1 were 
subjected to densitometric analysis, and densitometry units (U) were calculated relative to GAPDH. Data are the mean ± SD of six samples. 
*P < 0.05; ns, not significant (z-VAD-fmk-treated cells versus DMSO-treated cells in each transfection condition) according to Student 
t test. D., E. Mcl-1 downregulation by Notch silencing partially depends on degradation by proteasome. siCtrl, siNotch1 or siNotch2 
transfected cells were cultured for 72 hours in complete medium additioned, during the last 4 hours, with 2.5 µM proteasome inhibitor 
MG132 or 0.001% DMSO as control (n = 6). D. Accumulation of polyubiquitinated proteins, indicator of proteasome inhibition, and Mcl-1 
expression were analyzed by western blot on 15 µg whole-cell lysates. Protein loading was assessed by reprobing the blots with an anti-
GAPDH antibody. Data of CLL18 are representative of six samples. E. The blots of Mcl-1 were subjected to densitometric analysis, and 
densitometry units (U) were calculated relative to GAPDH. Data are the mean ± SD of six samples. *P < 0.05, **P < 0.01 (MG132-treated 
cells versus DMSO-treated cells in each transfection condition) according to Student t test. 
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Another mechanism controlling Mcl-1 protein 
expression is proteasomal degradation [26, 30, 31]. To 
determine whether the decrease in Mcl-1 levels induced 
by Notch targeting was due to proteasomal degradation, 
we tested the effect of the proteasome inhibitor MG132 (n 
= 6). It was added to siNotch1, siNotch2 and siCtrl cells 
during the last 4 hours of the 72-hour post transfection 
culture, and its action was demonstrated by the 
accumulation of polyubiquitinated proteins, an indicator 
of proteasome inhibition (Figure 3D). In siCtrl cells, 
MG132 increased Mcl-1 levels, indicating that in CLL 
cells cultured ex vivo, Mcl-1 is degraded by proteasome. 
In both siNotch1 and siNotch2 cells, MG132 prevented 
the loss of Mcl-1 protein which returned to levels observed 
in siCtrl cells (Figures 3D and 3E). These results suggest 
that Mcl-1 downregulation by Notch targeting depends, 
at least in part, on increased degradation by proteasome.
Mcl-1 downregulation by Notch silencing is 
accompanied by reduced eIF4E phosphorylation
Mcl-1 mRNA translation is highly dependent 
on the activity of the eukaryotic initiation factor 4E 
(eIF4E) [33], a key translation regulator associated with 
tumorigenesis [35, 36]. eIF4E is indeed frequently over-
expressed and over-activated in human cancers, and acts 
at a converging point of relevant oncogenic pathways. 
One pathway regulating eIF4E activity is mediated by 
the MAPK-interacting kinases 1 (MNK1) and MNK2, 
which are targets of the Ras/Raf/MAPK signaling and 
directly phosphorylate eIF4E at Ser209, a crucial event 
for its oncogenic activity [41]. Another pathway is 
mediated by the eIF4E-binding protein 1 (4E-BP1), a 
target of the PI3K/AKT/mTOR signaling, which, when 
is hypophosphorylated, prevents eIF4E activity through 
inhibitory interactions [42]. Based on these observations, 
we examined whether in CLL cells, Mcl-1 downregulation 
by Notch silencing was accompanied by effects on the 
expression and phosphorylation of eIF4E (Ser209), 
MNK1 (Thr197/202), and 4E-BP1 (Thr37/46 and Ser65). 
Consistent with previous studies [37], our results showed 
that all examined CLL cells (n = 6) expressed high levels 
of both total and phosphorylated eIF4E forms. eIF4E 
phosphorylation, but not expression, was reduced by 
either Notch1 or Notch2 targeting, and to a greater extent, 
by combined Notch1/2 targeting (Figures 4A and 4B). In 
contrast, expression and phosphorylation levels of MNK1 
and 4E-BP1 were not affected by either each single or 
combined Notch receptor downregulation (Figure 4A). 
These results indicate that Notch signaling controls eIF4E 
activity, but in doing this, it does not involve MNK1 
and 4E-BP1 regulation. These results, along with recent 
evidence that eIF4E contributes to CLL cell survival [37], 
also suggest that eIF4E activity is another target of the 
anti-apoptotic Notch signaling in CLL, in addition to Mcl-
1. 
Figure 4: Mcl-1 downregulation by Notch silencing is associated with reduced phosphorylation of eIF4E. CLL cells 
were transfected with control siRNA (siCtrl), Notch1 siRNA (siNotch1), Notch2 siRNA (siNotch2) or combined siNotch1 and siNotch2 
(siNotch1/2), as described in “siRNA transfection” and then cultured in complete medium for 72 hours (n = 6). A. Expression and 
phosphorylation of eIF4E (Ser209), 4E-BP1 (Thr37/46 and Ser65) and MNK1 (Thr197/202) were analyzed by western blot on 15 µg 
whole-cell lysates, using antibodies able to detect total and phosphorylated forms. Protein loading was assessed by reprobing the blots 
with an anti-GAPDH antibody. Data of CLL7 and 18 are representative of six samples. B. The blots of phosphorylated eIF4E (Ser209) 
were subjected to densitometric analysis, and densitometry units (U) were calculated relative to total eIF4E. Data are the mean ± SD of six 
samples. *P < 0.05, **P < 0.01 (each siNotch transfection condition versus siCtrl) according to Student t test.
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DISCUSSION
 In the present study, we have identified in the 
anti-apoptotic Mcl-1 protein and in the key translational 
regulator eIF4E, two targets of the pro-survival activity 
of Notch signaling in CLL cells. These findings are 
interesting because Mcl-1 and eIF4E are oncogenic 
in several malignancies [26, 35], including CLL. In 
this leukemia, both proteins are important mediators 
of cell survival [19, 20, 37], with Mcl-1 which is 
closely associated with adverse prognosis [21, 22] and 
chemoresistance [23, 24]. 
Specifically, we have shown that the increase in 
CLL cell apoptosis induced by either Notch1 or Notch2 
genetic inhibition is accompanied by Mcl-1 protein 
downregulation. In contrast, the levels of Bcl-2 protein 
remained unaffected indicating that Bcl-2 is not a target 
of the anti-apoptotic signaling of Notch in CLL cells and 
that Mcl-1 reduction is not due to a general effect of Notch 
silencing. This observation along with the evidence that 
the decrease in Mcl-1 levels induced by Notch silencing 
was observed in the vast majority of CLL cells with 
Notch-dependent viability (83.3%), but not in CLL cells 
whose viability was independent of Notch, suggest that 
Mcl-1 is important for Notch-mediated CLL cell survival. 
Thus, one of the mechanisms by which Notch1 and 
Notch2 sustain CLL cell survival is by maintaining the 
constitutive high levels of Mcl-1. 
In CLL cells, several pro-survival signals have been 
implicated in promoting Mcl-1 expression, including 
those mediated by STAT3 [27], NF-kB [43], and Syk/
AKT pathways [20, 44]. This is the first evidence that in 
CLL cells, Mcl-1 expression is also sustained by Notch 
signaling. This effect of Notch is not due to transcriptional 
regulation because reduction in Mcl-1 levels induced 
by Notch1 and Notch2 targeting is not accompanied 
by changes in Mcl-1 mRNA expression. Mcl-1 
downregulation by Notch targeting is also independent 
of cleavage by caspases, but, as shown in studies of 
pharmacologic proteasome inhibition, it is partially due 
to increased Mcl-1 proteasome-mediated degradation, 
suggesting that Notch signaling controls this process, and 
contributes to stabilize Mcl-1 levels by interfering with 
it. Whether in CLL cells, Notch receptors act directly on 
Mcl-1 protein to stabilize it, as Notch1 does to stabilize 
XIAP protein [16], or indirectly, by influencing some of 
the pathways which regulate Mcl-1 proteasome-mediated 
degradation in these cells, including the Syk/PKCδ [45] 
and AKT/GSK3 [46] pathways, remains to be defined. 
Furthermore, the evidence that Mcl-1 
downregulation by Notch targeting is accompanied by a 
decreased activity of eIF4E, an essential factor for Mcl-1 
translation, also suggests that Notch signaling may control 
Mcl-1 expression by regulating its biosynthesis. Further 
studies will be needed to define this point and to clarify 
the mechanisms whereby Notch signaling sustains eIF4E 
activity in CLL cells, given that Notch targeting does 
not have any effect on the phosphorylation levels of 4E-
BP1 and MNK1, which in other cell types, are two key 
upstream regulators of eIF4E activity [41, 42]. 
The impact of Notch signaling on Mcl-1 expression 
in CLL cells is also supported by the evidence that 
the combined Notch1/2 downregulation induces a 
higher reduction of Mcl-1 levels than that induced 
by downregulating each single receptor. However, 
these results seem discordant with the observation that 
combined Notch1/2 silencing does not enhance CLL 
cell apoptosis induced by downregulating each single 
receptor. A possible explanation is that the anti-leukemic 
activity of a strong Notch downregulation is limited by 
compensatory survival mechanisms, suggesting that 
inhibition of Notch signaling alone is not sufficient to kill 
all leukemic cells. This is consistent with the evidence 
that in several malignancies, the best clinical activity 
of Notch-targeted therapies was observed when the 
specific Notch inhibitors, including γ-secretase inhibitors 
(GSI) or monoclonal antibodies to Notch receptors or 
Notch ligands, were administered in combination with 
conventional chemotherapy or other targeted agents 
[47]. In line with this evidence, even in CLL cells, it has 
been recently demonstrated that the clinically relevant 
GSI PF-03084014 improves the pro-apoptotic effect of 
fludarabine [48]. This occurs because Notch inhibition 
overcomes the resistance mechanisms activated in CLL 
cells by fludarabine [23], including increased NF-kB 
activation [48] and Mcl-1 expression [21]. In this context, 
a critical role of Notch in regulating NF-kB pathway has 
been previously described in T-cell leukemia [15, 49] and 
a role of Notch in controlling Mcl-1 expression is here 
demonstrated in CLL. 
Another important aspect of this study is that Notch 
signaling also contributes to Mcl-1 accumulation induced 
by survival micro-environmental stimuli. Specifically, 
we demonstrate that IL-4, known to induce in CLL cells 
an increased Mcl-1-mediated cell survival [39], also 
enhances Notch1 and Notch2 activation. Interestingly, 
combined Notch1/2 downregulation partially prevents the 
increase in both CLL cell survival and Mcl-1 expression, 
suggesting that Notch targeting, in addition to reducing 
the constitutive Mcl-1 levels, is also able to prevent Mcl-
1 accumulation induced by micro-environmental stimuli. 
This effect of Notch downregulation is important because 
in CLL, the major resistance mechanisms to current 
chemotherapy, including Mcl-1 expression, are highly 
favored by the microenvironment [38].
Overall, Notch signaling sustains CLL cell survival 
by promoting Mcl-1 expression and eIF4E activity. These 
findings along with the evidence that both Mcl-1 and 
eIF4E contribute to survival and chemotherapy resistance 
of CLL cells highlight the importance to target Notch 
signaling for CLL treatment, especially in combination 
with agents whose poor efficacy is mainly due to the 
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elevated Mcl-1 expression and eIF4E activity detected in 
these leukemic cells. 
MATERIALS AND METHODS
Patients
Twenty-two CLL patients entered this study. 
Diagnoses of CLL were based on Stanford criteria defined 
by the National Cancer Institute-sponsored Working 
Group [50], and clinical staging was based on the Binet 
classification [51]. This study was approved by the local 
Ethics Committee, and all patients signed informed 
consent in accordance with the Declaration of Helsinki. 
CLL cell isolation
Peripheral blood mononuclear cells were isolated 
from heparinized blood of CLL patients by Ficoll density-
gradient centrifugation (Nycomed, Oslo, Norway). 
Monocytes were removed by plastic adherence, and T 
cells by sheep erythrocyte rosetting. All CLL samples 
contained more than 96% CD19+/CD5+ CLL cells, as 
assessed by flow cytometry (EPICS-XL-MCL; Beckman 
Coulter, Fullerton, CA).
CLL clinical laboratory characteristics
IgVH mutations, CD38 surface and ZAP70 
intracellular expression were analyzed as previously 
reported [8]. Cytogenetic abnormalities were examined by 
fluorescent in situ hybridization (FISH) using probes for 
chromosomes 11, 12, 13, 14 and 17. NOTCH1 exon 34 
mutations were analyzed as previously reported and the 
percentage of mutant allele burden was determined using a 
semi-quantitative assay on the basis of Genescan analysis 
[4]. Table 1 gives clinical and biological characteristics of 
CLL patients.
siRNA transfection
CLL cells (12 x 106) were resuspended in 100 μl 
Cell Line Solution Kit V (Lonza Group Ltd, Basel, 
Switzerland) with ON-TARGETplus SMARTpool small 
interfering RNA (siRNA) to Notch1 (0.5 μM), Notch2 
(0.5 μM) or ON-TARGETplus siCONTROL nontargeting 
pool as negative control (all from Dharmacon RNA 
Technologies, Lafayette, CO). In the case of combined 
Notch1 and Notch2 silencing, 0.25 μM per siRNA was 
added. Cells were then transfected with the Amaxa 
Nucleofector II device (program U-013) and cultured for 
72 hours in 12-well plates in complete medium consisting 
of RPMI 1640 supplemented with 10% heat-inactivated 
fetal bovine serum (Hyclone Laboratories, Logan, UT), 
2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin (all from Invitrogen, Milan, Italy). In some 
experiments, transfected cells were incubated with 25 ng/
ml recombinant human IL-4 (Immunotools, Friesoyte, 
Germany), 50 µM pan-caspase inhibitor z-VAD-fmk or 2.5 
µM proteasome inhibitor MG132 (both from Calbiochem, 
La Jolla, CA). The inhibitors z-VAD-fmk and MG132 
were dissolved in DMSO and diluted in complete medium 
at the used concentrations. DMSO concentrations, which 
did not exceed 0.005%, did not affect CLL cell responses. 
IL-4 and z-VAD-fmk were added at the beginning of the 
72-hour post transfection culture and maintained until cell 
collection, whereas MG132 was added during the last 
4-hour culture. 
Analysis of cell viability and apoptosis
Cell viability and apoptosis were assessed by flow 
cytometric analysis (EPICS-XL-MCL) after Annexin 
V-fluorescein isothiocyanate/propidium iodide staining, 
performed using a commercial kit (Immunotech, Beckman 
Coulter) according to the manufacturer’s instructions. 
Western blot analysis
Whole-cell lysates were extracted in RIPA buffer. 
Equal amounts of proteins were separated by 7.5% SDS-
PAGE and transferred to nitrocellulose membranes, 
which, after blocking, were incubated with primary 
antibodies to: Notch1 (clone bTAN20) and Notch2 (clone 
C651.6DbHN), developed by Spyros Artavanis-Tsakonas, 
obtained from DSHB developed under the auspices of 
the NICHD, and maintained by Iowa University; Mcl-
1 (Santa Cruz Biotechnology, Santa Cruz, CA); Bcl-2 
(DakoCytomation, Milan, Italy); phospho-eIF4E (Ser209), 
total eIF4E, phospho-4E-BP1 (Ser65), phospho-4E-BP1 
(Thr37/46), total 4E-BP1, phospho-MNK1 (Thr197/202), 
total MNK1 and PARP (Cell Signaling Technology, 
Beverly, MA); ubiquitinated proteins (BIOMOL Research 
Laboratories, Plymouth Meeting, PA) and GAPDH 
(Sigma-Aldrich, St. Louis, MO). Signals were detected 
using appropriate horseradish peroxidase-conjugated 
secondary antibodies and the ECL system (GE Healthcare, 
Milan, Italy). Densitometric analysis was performed using 
Quantity One software (Bio-Rad, Milan, Italy).
Real-time quantitative PCR
Total RNA was isolated using Trizol (Invitrogen) 
and 1 μg reverse-transcribed using RT-kit plus (Nanogen 
Advanced Diagnostics, Milan, Italy). Real-time 
quantitative PCR was performed with PCR Master Mix 
Power SYBR Green (Applied Biosystems, Warrington, 
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UK), using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems). The primer sequences used for 
MCL-1 were forward: 5’- GAG ACC TTA CGA CGG 
GTT-3’ and reverse: 3’-TTT GAT GTC CAG TTT CCG-
3’ (Invitrogen). Relative fold change was normalized to 
GAPDH and calculated using the 2-ΔΔCt method.
Statistical analysis
Statistical differences between mean values were 
evaluated using the Student t test. The minimal level of 
significance was P < 0.05. 
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